Related Experiment Video
Updated: Jan 31, 2026
Surgical Models of Gastroesophageal Reflux with Mice
Published on: August 25, 2015
Infant Reflux Trial: study protocol for a multicentre randomized controlled trial on the treatment of
Natalia Krantz Barkholt1,2, Kasper Dalby3, Christian Backer Mogensen4,5
1Pediatric Department, University Hospital of Southern Denmark, Kresten Philipsens Vej 15, 6200, Aabenraa, Denmark. Natalia.Barkholt@rsyd.dk.
Insights
This study compares a cow's milk protein-free diet and proton-pump inhibitor therapy for infant gastroesophageal reflux disease (GERD). It aims to determine the most effective treatment for reducing infant GERD symptoms and improving outcomes.
Area of Science:
- Pediatrics
- Gastroenterology
- Clinical Trials
Background:
- Gastroesophageal reflux disease (GERD) is prevalent in infants under one year.
- Cow's milk protein allergy is a key contributor to infant GERD.
- Current guidelines suggest dietary changes before medication, but evidence is limited.
Purpose of the Study:
- To evaluate the efficacy of a cow's milk protein-free diet versus proton-pump inhibitor (PPI) therapy for infant GERD.
- To compare these interventions against a placebo control.
- To provide evidence-based guidance for infant GERD treatment.
Main Methods:
- A multicenter, randomized, placebo-controlled trial involving 96 infants diagnosed with GERD.
- Three parallel groups: cow's milk protein-free diet, PPI, and placebo.
- Primary outcome: reduction in regurgitation episodes over 4 weeks.
Main Results:
- The trial is designed to provide evidence on the efficacy of interventions.
- Findings will compare treatment effects against natural symptom resolution.
- Specific IgE to cow's milk protein will be quantified.
Conclusions:
- This trial will offer crucial insights into optimal infant GERD management.
- Results will guide clinical practice for treating GERD in infants.
- Improved treatment strategies can enhance infant health and family well-being.
Background:
Gastroesophageal reflux disease (GERD) is a common condition in infants below 1 year of age. Symptoms include frequent regurgitation, failure to thrive, food refusal, irritability, and back arching. While many infants experience some degree of physiological reflux, persistent or severe symptoms may indicate GERD. One important underlying cause of GERD in infants is allergy to cow's milk protein. Current international guidelines recommend a trial of a cow's milk protein-free diet prior to initiating medical therapy with a proton-pump inhibitor. However, the efficacy of both the diet and the medication remains insufficiently studied. With only a few randomized trials available, further evidence is needed to ensure infants receive the most appropriate treatment.
Methods:
This protocol describes a multicentre, randomized placebo-controlled trial, enrolling 96 infants with a clinical diagnosis of GERD at 3 paediatric centres in Southern Denmark. Eligible participants will be randomly assigned to one of three parallel groups: (1) A diet group receiving a cow's milk protein-free diet, (2) a medicine group treated with a proton-pump inhibitor, and (3) a control group receiving a placebo medicine. Both the PPI group and the control group will be blinded to the allocation and will continue a diet containing cow's milk protein. The intervention period is 4 weeks. The primary outcome is the reduction in the number of regurgitation episodes. Secondary outcomes include weight gain and reduction in GERD-related symptoms. Symptom data will be reported by parents using a digital application, and specific IgE to cow's milk protein will be quantified in all participants. Infants in the diet group who respond positively will undergo an oral milk challenge to confirm allergy to cow's milk protein.
Discussion:
This trial is designed to provide evidence on the efficacy of a cow's milk protein-free diet and proton-pump inhibitor therapy for infant GERD. Both interventions are evaluated against a control group, ensuring that any improvement exceeds the natural course of symptom resolution over time. The findings will provide valuable insights to guide clinical practice and enhance treatment strategies for infant GERD, a condition with a substantial impact on infant health and family well-being.
Prospective Trial Registration:
ClinicalTrials.gov NCT06255886. Registered on February 13, 2024.
Clinicaltrials:
eu EU-CT: 2022-502770-16-00. Registered on November 4, 2024.
Related Concept Videos
01:29Gastroesophageal Reflux Disease I: Meaning and Pathophysiology
01:29Gastroesophageal Reflux Disease II: Clinical Features and Management
Clinical Manifestations
GERD presents itself in a multitude of ways, with symptoms varying from person to person. The hallmark symptoms are...
01:11Clinical Trials: Overview
01:12Trial and Error and Algorithm
01:16Clinical Trials
There are four phases in a clinical trial. A phase one...
01:29Drug Dosing: Infants and Children